Literature DB >> 3534001

Abnormal cytolytic activity of lymphocyte function-associated antigen-1-deficient human cytolytic T lymphocyte clones.

S J Mentzer, B E Bierer, D C Anderson, T A Springer, S J Burakoff.   

Abstract

The involvement of the lymphocyte function-associated antigen-1 (LFA-1) membrane molecule in cytolytic T lymphocyte (CTL) interactions with lymphoid target cells was investigated using CTL clones derived from two patients with a heritable deficiency of LFA-1. LFA-1 surface expression on the CTL clones was 1% of the normal level of LFA-1, unchanged with prolonged culture, and identical on 14 different CTL clones. The function of the LFA-1 molecule was addressed using the LFA-1-deficient CTL clones and LFA-1-deficient lymphoid target cells. The lytic activity of the LFA-1-deficient CTL clones was 43% of control when tested against a target cell line expressing normal levels of LFA-1 and less than 10% of control when tested against an LFA-1-deficient target cell line. These results demonstrate a direct involvement of LFA-1 in CTL-mediated cytolysis and suggest a more general dependence on LFA-1 in lymphoid cell-cell interactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534001      PMCID: PMC423840          DOI: 10.1172/JCI112725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Interferon-gamma induction of LFA-1-mediated homotypic adhesion of human monocytes.

Authors:  S J Mentzer; D V Faller; S J Burakoff
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

2.  LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation.

Authors:  A M Krensky; E Robbins; T A Springer; S J Burakoff
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

3.  The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions.

Authors:  A M Krensky; F Sanchez-Madrid; E Robbins; J A Nagy; T A Springer; S J Burakoff
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

4.  Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2.

Authors:  P Parham; W F Bodmer
Journal:  Nature       Date:  1978-11-23       Impact factor: 49.962

5.  Deficiency of a leukocyte surface glycoprotein (LFA-1) in two patients with Mo1 deficiency. Effects of cell activation on Mo1/LFA-1 surface expression in normal and deficient leukocytes.

Authors:  M A Arnaout; H Spits; C Terhorst; J Pitt; R F Todd
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis.

Authors:  T A Springer; W S Thompson; L J Miller; F C Schmalstieg; D C Anderson
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

7.  Human lymphocyte function associated antigen-1 (LFA-1): identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity.

Authors:  C F Ware; F Sanchez-Madrid; A M Krensky; S J Burakoff; J L Strominger; T A Springer
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

8.  Immunologic studies with LFA-1- and Mo1-deficient lymphocytes from a patient with recurrent bacterial infections.

Authors:  F Miedema; P A Tetteroo; F G Terpstra; G Keizer; M Roos; R S Weening; C M Weemaes; D Roos; C J Melief
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

9.  LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes.

Authors:  S J Mentzer; S H Gromkowski; A M Krensky; S J Burakoff; E Martz
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

10.  A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.

Authors:  F Sanchez-Madrid; J A Nagy; E Robbins; P Simon; T A Springer
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.